Our analysis revealed that there is a higher FUNDC2 expression in breast cancer tissues compared to the non-tumor controls, based on a cohort of 140 breast cancer cases, 33 non-tumor benign lesions, 82 non-TNBC cases, and 58 TNBC cases. Here, FUNDC2 is linked to breast carcinoma.